September 2026 - Page 4 of 12

Release – Xerox Announces Major Production Print Portfolio Expansion at PRINTING United Expo 2026

Posted on September 23, 2026September 23, 2026 by [email protected]

September 23, 2026

LAS VEGAS–(BUSINESS WIRE)–Sep. 23, 2026– Xerox Holdings Corporation (NASDAQ: XRX) today announced a major production print portfolio expansion as part of PRINTING United Expo 2026, introducing three new press platforms and enhancements to existing presses.

With these introductions, Xerox is deepening its commitment to production print with an inkjet portfolio spanning cut-sheet and continuous-feed, alongside a new 6-color flagship press for graphic arts. Integrated with the Xerox end-to-end production ecosystem of presses, workflow automation software, media expertise and lifecycle services, the new offerings extend specialty color and intelligent automation capabilities across the broader portfolio, helping print providers bring more work in-house, streamline production and pursue new revenue opportunities.

“PRINTING United is the ideal stage to show how Xerox is driving the future of production print,” said Terry Antinora, President, Global Production Print Services at Xerox. “We’re giving print providers a complete inkjet portfolio, embellishment, intelligent automation, and AI-powered tools that help them grow, differentiate, and win. Everything we’re launching is designed to improve customer profitability — not just increase print volume.”

Attendees can explore the following additions to the Xerox production print portfolio:

Xerox^® Proficio™ Jet CS1100: A B3 cut-sheet inkjet press that delivers speeds of up to 300 images per minute. New Xerox-developed printheads and a high-definition ink formulation deliver 1200 × 1200 dots per inch resolution with 2-bit variable-drop imaging for precise dot placement. A scalable drying architecture supports media up to 350 grams per square meter, including coated stocks. The platform enables print providers to shift a wider range of work, from transactional and direct mail to graphic communications and commercial print, onto a single press without compromising quality.
Xerox^® Proficio™ Jet CF1200: An industrial continuous-feed inkjet press that delivers speeds of up to 525 feet per minute at 1200 dpi within a compact 28-foot footprint. The smallest 20-inch press in its class handles between 4 million and 30 million Letter / A4 impressions per month, helping high-volume print providers increase capacity, operate more efficiently and protect margins.
Xerox^® Proficio™ PX700 FLX: A new graphic arts production press that delivers speeds of up to 120 pages per minute and supports up to six colors inline at rated speed. New Fluorescent Green specialty toner further expands the color gamut and improves RGB accuracy when paired with Fluorescent Pink. Intelligent automation helps reduce operator intervention and improve consistency, enabling print providers to create differentiated, high-value applications.
Xerox^® Proficio™ PX300 and PX500 feature updates: Enhanced with new Beyond CMYK and fifth-color options, including Gold, Silver and White, the Proficio PX300 and Proficio PX500 expand opportunities for metallic effects and printing on dark and transparent media. The Proficio PX300 now also features the Xerox^® PredictPrint Media Manager, which uses AI-assisted cloud intelligence to simplify media setup and optimize color stability.

At PRINTING United, Xerox will host demonstrations and discussions on generative AI for specialty print, workflow analytics and automation through Xerox^® FreeFlow^® Core and Xerox^® FreeFlow^® Vision Connect Software, and generative AI, along with business development resources available through the Genesis Initiative. The Xerox Genesis Initiative helps creative teams maximize the value of Beyond CMYK technologies through specialty inks and embellishments, and application development resources.

To learn more, visit Xerox at PRINTING United booth #N6729 or explore the company’s production print portfolio at Xerox.com.

About Xerox Holdings Corporation (NASDAQ: XRX)

Xerox is a global technology company with more than 120 years of innovation leadership. We design, manufacture, deliver, and support print, IT, and digital services for nearly 200,000 clients worldwide. Our integrated, AI-powered portfolio includes managed and production print, document management, workflow automation, cybersecurity, cloud managed services, IT infrastructure and collaboration technology. Serving clients from growing SMBs to 90 percent of the Fortune 500, Xerox supports leading healthcare, government, financial services, education, legal, retail and commercial organizations. Through direct sales and a global network of channel partners, we deliver the technology, expertise, and support organizations need to operate efficiently, securely and at scale.

Note: To receive RSS news feeds, visit www.news.xerox.com. For open commentary, industry perspectives and views, visit www.linkedin.com/company/xerox or www.youtube.com/XeroxCorp.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260923599586/en/

Media Contact
Justin Capella, Xerox, [email protected]

Source: Xerox Holdings Corporation

Release – NN, Inc. Raises Full-Year 2026 Guidance Ranges for Net Sales and Adjusted EBITDA

Posted on September 23, 2026September 23, 2026 by [email protected]

Research News and Market Data on NNBR

PDF Version

CHARLOTTE, N.C., Sept. 22, 2026 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR) a global leader in precision manufacturing, today announced that it is raising its full-year 2026 guidance ranges for Net Sales and Adjusted EBITDA.

Updated Full-Year 2026 Guidance

Metric	Prior Guidance	Updated Guidance
Net Sales	$460 million – $480 million	$470 million – $490 million
Adjusted EBITDA	$55 million – $65 million	$58 million – $68 million

Management’s updated guidance for 2026 Net Sales at midpoint is $480 million, up $58 million, or 14% versus full-year 2025 Net Sales.

Management’s updated guidance for 2026 Adjusted EBITDA at midpoint is $63 million, up $14 million, or 29% versus full-year 2025 Adjusted EBITDA.

Chief Executive Officer Harold Bevis commented, “Our business continues to build momentum as we ramp up in our key growth markets of Data Center, Defense & Electronics, and Medical, where demand for our solutions remains strong and actively expanding. Our year-to-date results and year-to-go forecast underpin this improved guidance and reflect the steady performance our growth and cost programs.

NN is continuing to invest forward in its 5 Pillar growth end markets and this is translating to increased success and higher results. Raising our full-year 2026 guidance for net sales and adjusted EBITDA reflects our confidence in the performance of the business. We remain focused on our balanced plans for delivering profitable growth and improved cost productivity for our customers and shareholders.”

NN, Inc. will provide additional detail and updated guidance when it reports third quarter 2026 results on October 28, 2026.

About NN, Inc.
NN, Inc. (NASDAQ: NNBR) is an entrepreneurial manufacturing company specializing in manufacturing micron-toleranced precision metal componentry for high-growth end markets, especially Data Center, Electric Grid, Medical, Defense, and High-Value Vehicle systems. Founded in 1980, NN serves over 700 customers on 4 continents through its 2,550 person workforce operating out of 27 global plants. This footprint enables rapid innovation and global scaled solutions. For more information, visit nninc.com.

Forward Looking Statements
This press release may contain forward-looking statements regarding our business, operations, and financial performance. Such statements are based on current expectations and assumptions that are subject to a number of risks and uncertainties. Actual results could differ materially. Please refer to our most recently filed Form 10-K and our Form 10-Q for the period following that Form 10-K, including the risk factors described therein. We undertake no obligation to update any forward-looking statement, except as required by law. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.

This press release contains certain financial measures not presented in accordance with U.S. generally accepted accounting principles (“GAAP”) such as adjusted EBITDA (the “non-GAAP financial measures”). These non-GAAP financial measures are not calculated in accordance with GAAP and should not be considered in isolation from, or as a substitute for, the most directly comparable GAAP measures, and may not be comparable to similarly titled measures used by other companies. Management uses these non-GAAP financial measures, together with the comparable GAAP measures, to evaluate the Company’s operating performance and underlying business trends across periods on a consistent basis, and to assist in operational and financial decision-making, including with respect to internal budgeting and resource allocation. Reconciliations of each non-GAAP financial measure to its most directly comparable GAAP measure are set forth in the tables accompanying this presentation. A reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP measures is not provided because the Company cannot reasonably predict certain items necessary for such reconciliation without unreasonable efforts.

Investor Relations:
Joe Caminiti
[email protected]
312-445-2870

Oil Just Fell to a Two-Week Low. Saudi Arabia and Iraq Are Quietly Rerouting Around the Strait of Hormuz

Posted on September 23, 2026September 23, 2026 by [email protected]

Oil prices extended a six-session decline Wednesday, with Brent crude falling to $98.16 a barrel and West Texas Intermediate dropping to $89.01, both settling at roughly two-week lows. Brent closed below $100 a barrel Tuesday for the first time since September 8, a notable reversal after weeks of escalation-driven price spikes that we’ve tracked closely throughout this conflict.

Two forces are driving the decline, and both matter for understanding where oil heads next. The first is diplomatic. President Trump warned Tuesday that the US could take severe action against Iran, while simultaneously saying his envoys had held productive talks with Iranian mediators in New York and describing real momentum toward reaching a deal to end the nearly seven-month war. Markets appear to be choosing to price in the possibility of talks succeeding, even amid continued tough rhetoric on both sides.

The second, more concrete factor is supply, and it’s arguably the more important development. Saudi Arabia restarted its East-West Pipeline to the Red Sea on Tuesday, a route that reroutes roughly 4 million barrels per day, about 4% of global oil supply, around the Strait of Hormuz entirely. The pipeline had been shut since September 11 following drone attacks Saudi Arabia has blamed on Iraqi militia forces. Saudi Arabia is also now offering additional barrels to Asian refiners for pickup outside the strait altogether. Iraq is following a similar playbook, with its oil minister confirming exports have climbed above 3 million barrels per day and stating the country expects to boost shipments routed through Turkey to more than 600,000 barrels per day. Shiptracking data shows Iraqi exports climbing in August from July’s levels, though they still remain below the roughly 3.4 to 3.7 million barrel per day pace seen before the war began.

Adding further downward pressure, industry data released Tuesday showed US crude inventories rose by 1.8 million barrels last week, catching analysts off guard, who had broadly expected a decline.

For investors tracking the small and microcap space, this shift is worth watching closely, and it cuts in the opposite direction from what we detailed when covering diesel’s all-time high and the broader oil surge earlier this month. Consumer-facing companies in transportation, logistics, and hospitality, squeezed hard by the run-up in fuel costs, stand to benefit if this decline holds and extends toward the pump, a group that includes companies like Commercial Vehicle Group, a supplier to the trucking industry, and The ONE Group Hospitality, a restaurant operator directly exposed to consumer discretionary spending. Domestic energy producers, conversely, face renewed margin pressure as prices retreat from the highs that supported their economics all summer, a dynamic worth watching for companies like InPlay Oil and Alliance Resource Partners. Whether this reversal proves durable likely depends on whether the diplomatic momentum Trump described translates into an actual agreement, or whether these alternative supply routes simply prove temporary workarounds to a conflict still very much unresolved.

Eledon Pharmaceuticals (ELDN) – Tegoprubart Extension Study Maintains Improvement Over Tacrolimus

Posted on September 23, 2026September 23, 2026 by [email protected]

Wednesday, September 23, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Long-Term Data Updated At Transplant Conference. Eledon presented an update to the Phase 2 BESTOW Extension study at the International Congress of The Transplantation Society. Analysis up to 24 months after transplantation showed that patients treated with tegoprubart had statistically significant improvements in kidney function compared with patients treated with tacrolimus. Separately, tegoprubart has also received Fast Track designation from the FDA in the kidney transplant indication.

Updated Extension Study Data. Patients completing the BESTOW trial were entered into an Extension Stage to follow outcomes after the trial period ended. At 18, 21, and 24 months, tegoprubart patients had a higher eGFR of about 71 mL/min/1.73m2 compared with 58 mL/min/1.73m2 for tacrolimus, with differences that were statistically significant. Tegoprubart patients showed a continued improvement in eGFR after the trial, while tacrolimus patients showed a gradual but steady decline.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

Century Lithium Corp. (CYDVF) – Advancing Plans for a Stand-Alone Merchant Chlor-Alkali Plant

Posted on September 23, 2026September 23, 2026 by [email protected]

Wednesday, September 23, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Advancing a merchant chlor-alkali plant. Century Lithium plans to develop a commercial-scale chlor-alkali plant in the Western United States that would produce chlorine, hydrochloric acid, and sodium hydroxide from sodium chloride, water, and electricity. The plant is expected to initially produce at a rate of 300 short tons per day (st/d) of chlorine, with potential expansion to 600 st/d depending on regional demand and the supply needs of Angel Island.

Early offtake interest provides commercial support. Century has signed eight non-binding Memorandums of Understanding (MOUs) that could collectively fully utilize the plant’s initial production, while discussions with additional customers are ongoing. The company is evaluating sites in Nevada and Utah based on power, feedstock, rail access, permitting, and proximity to customers, with final site selection expected following completion of due diligence.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Noble Capital Markets Emerging Growth Virtual Equity Conference – October 2026 – Presenting Company Replays

Posted on September 23, 2026October 2, 2026 by cpatches

Investor / Attendee Registration

Learn More

October 1 Schedule

All times Eastern

**8:30am**
**Big Sky Industrial (BSIN)**
**Watch the Replay**

**9:00am**
**Charles River Associates (CRAI)**
**Watch the Replay**

**9:30am**
**CBAK Energy Technology (CBAT)**
**Watch the Replay**

**10:00am**
**SBC Medical Group Holdings (SBC)**
**Watch the Replay**

**10:30am**
**PEDEVCO (PED)**
**Watch the Replay**

**11:00am**
**Star Equity Holdings (STRR)**
**Watch the Replay**

**11:30am**
**Kodiak Copper (KDKCF)**
**Watch the Replay**

**12:00pm**
**Evolution Petroleum (EPM)**
**Watch the Replay**

**1:00pm**
**Alliance Entertainment Holding (AENT)**
**Watch the Replay**

**1:30pm**
**Sernova Biotherapeutics (SEOVF)**
**Watch the Replay**

**2:00pm**
**SKYX Platforms Corp. (SKYX)**
**Watch the Replay**

**2:30pm**
**Kuya Silver (KUYAF)**
**Watch the Replay**

**3:00pm**
**Faraday Future (FFAI)**
**Watch the Replay**

**3:30pm**
**Tectonic Metals (TETOF)**
**Watch the Replay**

**4:00pm**
**Agilyx ASA (AGXXF)**
**Watch the Replay**

**4:30pm**
**Power Metallic Mines (PNPNF)**
**Watch the Replay**

October 2 Schedule

All times Eastern

**8:30am**
**Avation PLC (AVAP.LN)**
**Watch the Replay**

**9:00am**
**Kaltura (KLTR)**
**Watch the Replay**

**9:30am**
**Idaho Copper (COPR)**
**Watch the Replay**

**10:00am**
**Sky Harbour (SKYH)**
**Watch the Replay**

**10:30am**
**Resolution Minerals Ltd. (RML)**
**Watch the Replay**

**11:00am**
**Bridger Aerospace Group** **(BAER)**
**Watch the Replay**

**11:30am**
**First Phosphate (PHOS)**
**Watch the Replay**

**12:30pm**
**Grid Metals (GRDM)**
**Watch the Replay**

**1:00pm**
**Birchtech Corp (BCHT)**
**Watch the Replay**

**1:30pm**
**Collective Mining (CNL)**
**Watch the Replay**

**2:00pm**
**Noble Roman’s, Inc. (NROM)**
**Watch the Replay**

**2:30pm**
**Vince Holding Corp (VNCE)**
**Watch the Replay**

**3:00pm**
**ARMOUR Residential REIT (ARR)**

Participating in 1×1 Meetings Only

Nvidia’s Stock Got Cheaper While Its Business Got Stronger

Posted on September 23, 2026September 23, 2026 by [email protected]

Here’s a genuinely strange fact about the world’s most valuable company. Nvidia shares are trading at less than 17 times expected profit over the next 12 months, the cheapest valuation the stock has carried in more than a decade. That multiple is roughly half what Nvidia commanded in 2025, when its revenue and profit growth were actually slower than they are now, and it’s down sharply from more than 25 times earnings estimates as recently as May.

Normally, a stock getting cheaper while its fundamentals get stronger would be viewed as an obvious buying opportunity. What makes this situation genuinely worth examining is that the market appears to be sending a very specific signal, expressing real skepticism about whether Nvidia’s current earnings power is sustainable, even as the numbers themselves remain extraordinary. Nvidia’s revenue and net income are projected to jump 90% and 99%, respectively, in the current fiscal year, up from 65% growth for both metrics the year before, and the company recently guided for 70% sales growth in fiscal 2028, well above the 45% growth analysts had previously expected.

The disconnect gets stranger when you compare Nvidia to its own sector. Nvidia shares are up 22% in 2026, the second-best performance among the Magnificent Seven behind only Apple. That sounds strong until you look at the rest of the semiconductor industry, which is up nearly 76% this year. Rivals Intel and AMD have each gained more than 180%, and memory chipmaker Micron has led the pack. Nvidia currently ranks as the fifth-worst performer within its own sector index, which as a whole trades at roughly 20 times estimated profit, still cheaper than Nvidia carried a year ago, but meaningfully richer than where Nvidia sits today. Nvidia’s CEO addressed this tension directly at a recent industry conference, describing the company as what he called the world’s first and only growth value stock, arguing it is simultaneously growing rapidly and becoming more undervalued at the same time, a combination he characterized as widely misunderstood by the market.

Part of what’s weighing on the valuation is margin pressure. Nvidia posted a 75% gross margin last quarter, but that figure is projected to shrink to below 72% in the fourth quarter before recovering, driven largely by rising costs for components like memory chips. There’s also a competitive undercurrent building. Several of Nvidia’s largest customers, including Meta and Alphabet, have been developing their own AI chips in-house, and as more hyperscalers pursue that path, some market strategists expect Nvidia’s dominant market position to erode gradually over time, which would put continued pressure on margins rather than allow them to recover.

Not everyone reads the setup as bearish, however. Other market observers argue the more relevant question is what would actually need to happen for Nvidia’s current valuation to be justified, either a meaningful pullback in hyperscaler AI spending or a regulatory shift that slows AI development materially, and neither scenario currently looks likely. Under that view, a stock priced as though slower growth is already baked in, while actual demand signals continue pointing higher, represents a favorable entry point rather than a warning sign.

For investors tracking the broader AI infrastructure and semiconductor supply chain, this divergence between Nvidia and its smaller, faster-moving peers is worth watching closely, a topic we’ve followed since the earlier days of the sector’s AI-driven repricing. Smaller companies supplying components, materials, and specialized hardware into this same ecosystem are, in effect, operating in a market where investors are actively debating whether the dominant player’s premium is deserved or overextended, a debate whose outcome will likely ripple through valuations across the entire chip supply chain, not just Nvidia’s own stock.

The AI Jobs Debate Is More Complicated Than It Looks

Posted on September 22, 2026September 22, 2026 by [email protected]

The early success of Meta’s Muse AI agent has reignited a question that has been building all year: if AI tools can perform tasks inside a company quickly and cheaply, how much longer do companies keep paying humans to do the same work? Apollo Global Management’s chief economist addressed that tension directly in a recent interview, suggesting the labor market impact of tools like Muse is still a waiting game, one where the full effect simply hasn’t shown up in the data yet.

The case for concern is real and growing. Block, the payments company led by Jack Dorsey, cut 40% of its staff this year. Layoffs have swept through Amazon, Dell, Oracle, Coinbase, Cloudflare, and Meta itself, several of which we’ve tracked closely as part of the broader corporate efficiency wave reshaping how companies think about headcount in the AI era. Uber recently announced it would cut 10% of its workforce to capture what it described as significant efficiencies. These are not struggling companies making defensive cuts, they are profitable, growing businesses choosing to operate with fewer people even as they invest heavily in AI capability, a pattern that has now repeated across enough companies to look structural rather than coincidental.

Staffing and workforce advisory firms sit closest to this shift and are worth watching as a real-time indicator of how it plays out. Companies like Kelly Services and Resources Connection, both providers of staffing and flexible workforce solutions, along with Information Services Group, which advises corporations on technology sourcing and digital transformation decisions, are positioned to see these dynamics well before they show up in national jobs data. If companies are genuinely substituting AI for headcount at scale, these firms would likely see it first in shifting client demand for permanent placements versus flexible or project-based talent.

But the labor market data complicates the doom-and-gloom narrative considerably. Through August, the US economy added roughly 640,000 net nonfarm payroll jobs, averaging about 80,000 new positions per month, numbers that don’t reflect a labor market in collapse. Apollo’s economist made a useful distinction on this point, noting that while tools like Muse will genuinely eliminate some jobs, the new products and business activity AI enables will also create employment elsewhere, meaning this isn’t simply a displacement story, it’s a broader story about how AI reshapes business dynamics and, ultimately, aggregate employment in ways that cut in both directions simultaneously.

There’s an added wrinkle worth watching closely. A recent Gartner survey projects that by 2029, roughly 30% of employees laid off due to AI will need to be rehired, at meaningfully higher cost than their original positions carried. That’s a notable admission that some of this year’s efficiency-driven cuts may prove to be overcorrections, companies discovering that certain roles genuinely required human judgment or oversight AI couldn’t fully replace, and having to pay a premium to bring that expertise back.

For investors, this debate is no longer background noise, it’s showing up directly in the data that moves markets. Monthly jobs reports, which we’ve covered closely as they’ve swung between blowout beats and unexpected losses this year, are taking on greater weight precisely because AI-driven labor market shifts are becoming a genuine wildcard in how those numbers get interpreted. For companies in the small and microcap space, this dynamic cuts two ways worth watching. Smaller companies with leaner existing headcount may be structurally better positioned to adopt AI efficiently without the large-scale layoffs playing out at bigger firms, while companies specifically building AI tools, agents, and workflow automation software for business customers sit squarely in the path of demand created by this exact shift. Whether AI ultimately proves to be a net job destroyer or a net job reshuffler remains genuinely unresolved, and that uncertainty itself is becoming a market-moving variable heading into the final months of the year.

Release – Nutriband Confirms Warrants Will Expire September 30 Without Extension or Repricing

Posted on September 22, 2026September 22, 2026 by [email protected]

Research News and Market Data on NTRB

GlobeNewswire

Tuesday, September 22, 2026, 8:00:00 AM EDT

ORLANDO, Fla., Sept. 22, 2026 (GLOBE NEWSWIRE) — Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) confirmed today that its outstanding warrants (NASDAQ:NTRBW) will expire on September 30, 2026 at 5PM ET as scheduled. The Company will not extend the expiration date and will not reprice the warrants.

Warrant holders may exercise at the current strike price of $6.43 per share until the expiration date. Warrants not exercised by that date will expire in their entirety and be removed from the NTRBW Nasdaq listing.

There are currently 910,904 warrants outstanding, representing $5,856,112 in potential proceeds to the Company if fully exercised at the $6.43 strike price.

Key dates and terms:

Expiration date: September 30, 20265PM ET
Strike price: $6.43 per warrant
Warrants outstanding: 910,904
No extension. No repricing.

Shareholders and warrant holders are advised to act before the deadline if they intend to exercise. Nutriband will continue to provide updates on Company developments in the coming weeks.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from the Company’s websites or any other website is not part of this press release.

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words “believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Contact Information:
Nutriband Inc.
Phone: 407-377-6695
Email: [email protected]

Source: Nutriband Inc.

Release – Power Metallic Extends Lion 25% Deeper as Power Metallic Intercepts 5.70 Meters of 14.00% CuEqRec¹ in Hole 26-125

Posted on September 22, 2026September 22, 2026 by [email protected]

Research News and Market Data on PNPF

Sep 22, 2026

TORONTO, Sept. 22, 2026 – Power Metallic Mines Inc. (the “Company” or “Power Metallic”) (TSXV: PNPN) (OTCBB: PNPNF) (Frankfurt: IVV1) is pleased to provide the first assays of extensional deep drilling of assay results from its Summer 2026 drill program. Prior to the summer drill program drilling concentrated on improving the density of drill intercepts for the recently announced MRE to increase the confidence of modelling Lion, particularly within the range of a potential future open pit, and to bring the vast majority of the known deposit as of the end of the winter program (end April 2026) to Drill Indicated category.

For the summer drill program Power Metallic has carried out widely spaced exploration drilling on geological and geophysical (EM) targets and more importantly begun a program of extending the Lion deposit to depth below the outline of the MRE model. The two holes reported here are the first assays to be completed on this deep drilling.

Hole PML-26-125 is the deepest assay results to date at Lion at a vertical depth of nearly 800m vertical depth, well below the current MRE. Prior to Hole PML-26-125 The deepest reported hole intersecting the core of the Lion shoot to date (PML-25-002) intersected 1.95 metres at 7.95% CuEqRec* at approximately 610 metres vertical depth. This hole was targeted on the projected center of the Lion plunge approximately 150m below the previous deepest hole and intersected 5.7m of massive to semi-massive copper sulphides (Table 1). An earlier drill hole, PML-26-121a targeted the western side of the projected plunge of Lion at a vertical depth of nearly 650 meters and intersected disseminated to semi-massive copper sulphides. A subsequent hole (PML-26-128) tested the eastern side of the interpreted Lion plunge at nearly 900 meters vertical depth, showing disseminated and massive veinlets of copper sulphides, with assays pending (Figure 1). All three of these holes firmly established that the Lion deposit continues at depth and has not been fully delineated.

Table 1: Lion Results – Summer 2026
Hole	From	To	Length	Au	Ag	Cu	Pd	Pt	Ni	CuEq Rec*
Hole	(m)	(m)	(m)	(g/t)	( g/t )	( %)	(g/t)	(g/t )	( %)	( %)
PML-26-121a	666.30	674.00	7.70	0.26	18.42	1.03	3.70	0.28	0.14	3.28
Including	666.30	671.00	4.70	0.35	28.37	1.51	6.45	0.45	0.14	4.92
Including	666.30	668.00	1.70	0.66	72.41	3.34	16.25	1.21	0.16	11.93
PML-26-125	845.80	851.50	5.70	0.30	61.57	11.42	2.48	0.26	0.41	14.00
Including	846.70	848.85	2.15	0.55	92.04	20.30	4.72	0.51	0.60	24.62

1Copper Equivalent Rec Calculation (CuEqRec1)

CuEqRec represents CuEq calculated based on the following metal prices (USD) : 2,360.15 $/oz Au, 27.98 $/oz Ag, 1,215.00 $/oz Pd, 1000.00 $/oz Pt, 4.00 $/lb Cu, 10.00 $/lb Ni and 22.50 $/lb Co., and recovered grades based on recent locked-cycle metallurgical recoveries by SGS Canada Inc (see press release Jan 21, 2006).
2 Reported length is downhole distance; true width based on model projections is estimated as 85% of downhole length

Figure 1 – Lion Deep Drill holes reported in this news release overlain on Lion zone MRE models (X-Section) and MRE block model (Long Section) with hole locations related to potential plunge extension below MRE models)

Power Metallic is expecting more assay results from the Lion deep drilling and regional exploration in the weeks to come.

Terry Lynch, CEO of Power Metallic, commented:
We are in the unique position due to the high grade and near surface nature of our project to advance development of what the world needs in Critical Minerals, namely Copper and PGEs, but also continue our multifaceted exploration approach to allow the resource to grow substantially between now and the end of 2027. Today’s results pushed us over 25% deeper than the deepest hole used in our recently announced MRE and it did so with significantly higher grades. We have visibility down over 50% deeper and visibly it looks like we are still in the Lion Zone. As we have seen with the great hit Talon Metals recently had deposits can get thicker and richer at depth. The blessing in Lion is our mineralization starts at surface and extends down making it very economic to mine and explore. We are excited to get back to exploration!

Qualified Person

Joseph Campbell, P. Geo, VP Exploration at Power Metallic, is the qualified person who has reviewed and approved the technical disclosure contained in this news release.

About Power Metallic Mines Inc.

Power Metallic is a Canadian exploration company focused on advancing the Nisk Project Area (Nisk–Lion–Tiger)—a high–grade Copper–PGE, Nickel, gold and silver system—toward Canada’s next polymetallic mine.

On 1 February 2021, Power Metallic (then Chilean Metals) secured an option to earn up to 80% of the Nisk project from Critical Elements Lithium Corp. (TSX–V: CRE). Following the June 2025 purchase of 313 adjoining claims (~167 km²) from Li–FT Power, the Company now controls ~330 km² and roughly 50 km of prospective basin margins.

Power Metallic is expanding mineralization at the Nisk and Lion discovery zones, evaluating the Tiger target, and exploring the enlarged land package through successive drill programs. Beyond the Nisk Project Area, Power Metallic indirectly has an interest in significant land packages in British Columbia and Chile, by its 50% share ownership position in Chilean Metals Inc., which were spun out from Power Metallic via a plan of arrangement on February 3, 2025.

It also owns 100% of Power Metallic Arabia which owns 100% interest in the Jabul Baudan exploration license in The Kingdon of Saudi Arabia’s Jabal Said Belt. The property encompasses over 200 square kilometres in an area recognized for its high prospectivity for copper gold and zinc mineralization. The region is known for its massive volcanic sulfide (VMS) deposits, including the world-class Jabal Sayid mine and the promising Umm and Damad deposit.

For further information, readers are encouraged to contact:
Power Metallic Mines Inc.
The Canadian Venture Building
82 Richmond St East, Suite 202
Toronto, ON

Neither the TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

QAQC and Sampling

GeoVector Management Inc (“GeoVector”) is the Consulting company retained to perform the actual drilling program, which includes core logging and sampling of the drill core.

All core in this news release is either HQ or NQ sized core. Drill core is re-fitted and measured. Geotech on core includes photographs (wet & dry), rock quality index, magnetic susceptibility, conductivity, and recovery estimates. Core is logged for lithology, mineralogy, and structural features, and sample intervals are delineated and tagged.

Sampled core is mechanically sawn, and half-core is retained for future reference. GeoVector’s QAQC program includes regular insertion of CRM standards, duplicates, and blanks into the sample stream with a stringent review of all results. QAQC and data validation was performed, and no material errors were observed.

All samples were submitted to and analyzed at Activation Laboratories Ltd (“Actlabs”), a commercial laboratory independent of Power Metallic with no interest in the Project. Actlabs is an ISO 9001 and 17025 certified and accredited laboratories. Samples submitted through Actlabs are run through standard preparation methods and analysed using RX-1 (Dry, crush (< 7 kg) up to 80% passing 2 mm, riffle split (250 g) and pulverize (mild steel) to 95% passing 105 μm) preparation methods, and using 1F2 (ICP-OES) and 1C-OES – 4-Acid near total digestion + Gold-Platinum-Palladium analysis and 8-Peroxide ICP-OES, for regular and over detection limit analysis. Pegmatite samples are analyzed using UT7 – Li up to 5%, Rb up to 2% method. Actlabs also undertake their own internal coarse and pulp duplicate analysis to ensure proper sample preparation and equipment calibration.

Cautionary Note Regarding Forward-Looking Statements

This message contains certain statements that may be deemed “forward-looking statements” concerning the Company within the meaning of applicable securities laws. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects,” “plans,” “anticipates,” “believes,” “intends,” “estimates,” “projects,” “potential,” “indicates,” “opportunity,” “possible” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, are subject to risks and uncertainties, and actual results or realities may differ materially from those in the forward-looking statements. Such material risks and uncertainties include, but are not limited to, among others; the timing for various drilling plans; the ability to raise sufficient capital to fund its obligations under its property agreements going forward and conduct drilling and exploration; to maintain its mineral tenures and concessions in good standing; to explore and develop its projects; changes in economic conditions or financial markets; the inherent hazards associates with mineral exploration and mining operations; future prices of nickel and other metals; changes in general economic conditions; accuracy of mineral resource and reserve estimates; the potential for new discoveries; the ability of the Company to obtain the necessary permits and consents required to explore, drill and develop the projects and if accepted, to obtain such licenses and approvals in a timely fashion relative to the Company’s plans and business objectives for the applicable project; the general ability of the Company to monetize its mineral resources; and changes in environmental and other laws or regulations that could have an impact on the Company’s operations, compliance with environmental laws and regulations, dependence on key management personnel and general competition in the mining industry.

Release – MAIA Biotechnology Reports Pivotal Phase 3 Clinical Trial Progress in Advanced Non-Small Cell Lung Cancer

Posted on September 22, 2026September 22, 2026 by [email protected]

Research News and Market Data on MAIA

September 22, 2026 8:47am EDT

Download as PDF

Strong pace of patient enrollment supports continued advancement toward regulatory milestones

Most recent assessment of novel telomere targeting agent sequenced with a checkpoint inhibitor showed 90.5% disease control rate (DCR) in heavily pretreated NSCLC

CHICAGO, Sept. 22, 2026 (GLOBE NEWSWIRE) — MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that enrollment has reached 65 patients in its ongoing pivotal Phase 3 trial, THIO-104, evaluating its novel telomere-targeting therapy as a third-line (3L) treatment for advanced non-small cell lung cancer (NSCLC). The THIO-104 trial currently has 38 trial sites activated in 6 foreign countries (Taiwan, Romania, Turkey, Georgia, Poland and Hungary).

“Reaching 65 randomized patients marks an important milestone in our Phase 3 trial. With additional clinical sites expected to begin enrolling patients, we remain on track to achieve our goal of more than 100 randomized patients by year-end,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “As we’ve stated previously, statistical assessments of the Phase 3 trial point to a very high probability of technical success for regulatory approval of ateganosine.¹ We believe third-line NSCLC is an excellent market entry segment due to the substantial unmet medical need in this large immunotherapy-resistant and chemotherapy-resistant population. No current standard of care exists in this NSCLC treatment setting and competition for clinical trial patients is limited.”

In its most recent assessment, ateganosine sequenced with a checkpoint inhibitor showed 90.5% interim disease control rate (DCR) in heavily pretreated 3L NSCLC in MAIA’s ongoing phase 2 THIO-101 clinical trial. This measure contrasts with reported 25%–35% DCRs for standard third-line chemotherapy regimens.

In July 2025, the U.S. Food and Drug Administration (FDA) granted Fast Track designation for ateganosine for the treatment of NSCLC. This designation allows for more frequent FDA communication, potential rolling review, and eligibility for Accelerated Approval and Priority Review. If approved, ateganosine will hold FDA New Chemical Entity (NCE) five-year marketing exclusivity. An NCE is a small molecule drug with a novel active ingredient that hasn’t been previously approved or marketed.

About Ateganosine

Ateganosine (THIO, 6-thio-dG or 6-thio-2’-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2’-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.

About MAIA Biotechnology, Inc.

MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.

About THIO-104 Phase 3 Clinical Trial

THIO-104 is a multicenter, open-label, randomized Phase 3 clinical trial, designed to evaluate ateganosine’s telomere-targeting anti-tumor activity when followed by PD-(L)1 inhibition in patients with advanced third-line NSCLC who previously did not respond or developed resistance to treatment regimens containing checkpoint inhibitor and/or chemotherapy and have progressed. The trial has two primary objectives: (1) to assess the clinical efficacy of ateganosine compared to investigator’s choice of chemotherapy, using median Overall Survival (OS) as the primary clinical endpoint (2) to evaluate the safety and tolerability of ateganosine in sequential combination with a checkpoint inhibitor. For more information on this Phase 3 trial, please visit ClinicalTrials.gov using the identifier NCT06908304.

Forward Looking Statements

MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as “may,” “might,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, “MAIA,” “Company,” “we,” “our,” and “us” refers to MAIA Biotechnology, Inc. and its subsidiaries.

Investor Relations Contact
+1 (872) 270-3518
[email protected]

¹ See latest MAIA investor presentation and 2026 shareholder letter at ir.maiabiotech.com/company-information/presentations.

Source: MAIA Biotechnology, Inc.

Released September 22, 2026

Release – Century Lithium Advances Plans for Chlor-Alkali Plant

Posted on September 22, 2026September 22, 2026 by [email protected]

Research News and Market Data on CYDVF

Plans Support Critical Minerals Supply Chain and Company’s Angel Island Lithium Project;
Eight Offtake MOUs Signed for Chlor-Alkali Products

September 22, 2026 – Vancouver, Canada – Century Lithium Corp. (TSXV: LCE) (OTCQX: CYDVF) (Frankfurt: C1Z) (“Century Lithium” or “the Company”) is pleased to announce its plans to develop a commercial-scale chlor-alkali plant (“CA Plant”). The CA Plant is intended to support the critical and strategic minerals supply chain in the Western United States and the Company’s 100%-owned Angel Island Lithium Project (“Angel Island” or the “Project”) in Esmeralda County, Nevada, USA, currently in the permitting phase.

“In the course of our work on Angel Island, Century Lithium identified chlor-alkali products as a fundamental component of the critical minerals supply chain,” said Bill Willoughby, President and CEO of Century Lithium. “We also recognized a regional opportunity in the Western U.S. for a plant producing these products. The proposed CA Plant has the potential to generate revenue on its own, train an operating team and reduce future reagent supply risk to Angel Island. Century Lithium has evaluated a number of potential sites for the CA Plant in Nevada and Utah that could meet its criteria for proximity to infrastructure and resources and expects to finalize a selection shortly. The Company has obtained non-binding offtake interest for production from the CA Plant from a number of companies and is actively pursuing project-level financing.”

Highlights

Chlor-alkali products are essential inputs across the critical minerals supply chain, supporting lithium and battery-materials processing, rare earth element separation, and precious and specialty metals production, in addition to broader industrial and household uses.
The proposed CA Plant would produce chlorine, hydrochloric acid and sodium hydroxide from sodium chloride, water and electricity, at a target commercial production rate of 300 short tons per day (“st/d”) of chlorine, with provision to double capacity to 600 st/d depending on regional demand and the supply needs of Angel Island.
Century Lithium has entered into eight non-binding Memoranda of Understanding (“MOU”) with third parties for offtake arrangements that could collectively account for the full initial production of the proposed CA Plant.
Candidate sites in Nevada and Utah were evaluated against feedstock, power, rail access, market proximity, land tenure, and permitting criteria.
The proposed CA Plant would use modern, proven technology in a location favorable for infrastructure development.
Site due diligence is underway; the next step will be securing project-level financing to fund property acquisition, front-end engineering and design (“FEED”) and permitting of the selected site.

Site Selection

The Company is in the process of selecting the preferred site for the CA Plant out of a number of candidate sites which included a combination of private industrial land, state land, and federally controlled land available under lease.

The site selection process has considered internal engineering and economic work and studies addressing equipment selection, power, water and sodium chloride supply, CA product handling and comparative site economics.

Relation to Angel Island

The Feasibility Study for Angel Island (Updated NI 43-101 Technical Report on the Feasibility of the Clayton Valley Lithium Project, Esmeralda County, Nevada, USA, January 3, 2026) includes an on-site chlor-alkali plant as the base case for the Project. The capital and operating estimates disclosed in the Feasibility Study are unchanged by this announcement. The proposed CA Plant in this announcement does not replace that facility, and none of its cost is added to Angel Island.

The economics of the proposed CA Plant are based solely on internal study and the assumption of commercial sales of all chlor-alkali products to third-party customers. No revenue, cost saving or capital credit associated with Angel Island is included in them, and the CA Plant is intended to be financed at the project level.

The supply of reagents from the proposed CA Plant to Angel Island would depend on the economics of transportation still to be determined. Century Lithium views the proposed CA Plant as a self-funding first step toward Angel Island rather than a change in the Company’s lithium strategy.

Offtake and Commercial Arrangements

Century Lithium has entered into eight non-binding MOUs with companies in various industrial and chemical sectors in the Western U.S. to supply them with chlorine, hydrochloric acid, and sodium hydroxide produced by the proposed CA Plant. The Company is also in discussions with other prospective purchasers of these products.

Project Financing

Century Lithium intends to finance the proposed CA Plant through non-dilutive financing at the project level. The capital structure under evaluation contemplates a combination of vendor financing associated with site acquisition, institutional preferred equity, prepayments and similar support from offtake counterparties, and non-dilutive United States government programs that may be available to domestic critical minerals and industrial capacity. The Company has engaged financial advisors and has commenced consultations with United States government financing agencies. Land acquisition and front-end engineering are expected to be funded first, with construction financing arranged following completion of FEED and definitive offtake agreements.

Century Lithium’s objective in structuring the proposed CA Plant separately is to fund it with capital appropriate to an industrial chemical asset with anticipated offtake, and to limit dilution to shareholders of Century Lithium. No financing has been secured at this time, and no definitive agreements have been entered into, and there is no assurance that financing will be available on acceptable terms or at all.

Next Steps

Due diligence is underway and includes property negotiations, project-level funding, and investigation of power supply terms with the serving utility, salt feedstock and transportation, water rights, land tenure and title, environmental condition, and the permitting pathway. Once the preferred site is selected and secured, the Company intends to advance the preferred site to FEED with a qualified engineering, procurement and construction contractor and to commence permitting, while continuing discussions with prospective commercial counterparties and sources of project financing. Long-lead electrical equipment is a recognized schedule constraint for United States chlor-alkali projects, and the Company is evaluating equipment sourcing in parallel with site selection.

ABOUT CENTURY LITHIUM CORP.

Century Lithium Corp. is an advanced-stage lithium development company focused on its 100%-owned Angel Island Lithium Project in Esmeralda County, Nevada. Angel Island hosts one of the largest known sedimentary lithium deposits in the United States and is designed with an integrated, end-to-end process to produce battery-grade lithium carbonate on-site to support the electric vehicle and battery storage markets.

The Company has developed a patent-pending process that incorporates hydrochloric acid leaching combined with direct lithium extraction to produce battery-grade lithium carbonate. As part of the integrated chlor-alkali process, Angel Island is designed to produce sodium hydroxide as a co-product, with planned surplus sales expected to lower operating costs, reduce reliance on externally sourced reagents, and minimize environmental impacts.

Century Lithium is currently advancing Angel Island through the permitting process.

Century Lithium trades on the TSX Venture Exchange under the symbol “LCE” the OTCQX under the symbol “CYDVF” and on the Frankfurt Stock Exchange under the symbol “C1Z”.

To learn more, please visit centurylithium.com.

ON BEHALF OF CENTURY LITHIUM CORP.

WILLIAM WILLOUGHBY, PhD, PE
President & Chief Executive Officer
For further information, please contact:
Spiros Cacos | Vice President, Investor Relations
Direct: +1 604 764 1851
Toll Free: 1 800 567 8181
[email protected]
centurylithium.com

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THE CONTENT OF THIS NEWS RELEASE.

Cautionary Note Regarding Forward-Looking Statements

This release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” and similar expressions suggesting future outcomes or statements regarding an outlook.

Forward-looking statements relate to any matters that are not historical facts and statements of our beliefs, intentions and expectations about developments, results and events which will or may occur in the future, without limitation, statements with respect to the potential development of a chlor-alkali plant, site selection, anticipated capacity and product slate, regional supply and demand conditions, and the intended financing structure and sources for the chlor-alkali plant, the anticipated benefits of the plant to the Angel Island Lithium Project, and anticipated engineering, permitting and financing activities and their timing. Forward-looking statements are based on assumptions management considers reasonable, including as to the availability of a suitable site, power, feedstock, permits, equipment and financing on acceptable terms, and as to regional demand. Actual results may differ materially. The Company has not made a construction decision, has not secured a site, and there is no assurance that any plant will be developed or that any memorandum of understanding will result in a definitive agreement. Readers are cautioned not to place undue reliance on forward-looking statements. The Company undertakes no obligation to update them except as required by law.

These and other forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein. These risks include those described under the heading “Risk Factors” in the Company’s most recent annual information form and its other public filings, copies of which can be found under the Company’s profile at www.sedarplus.ca. The Company expressly disclaims any obligation to update forward-looking information except as required by applicable law. No forward-looking statement can be guaranteed, and actual future results may vary materially. Accordingly, readers are advised not to place reliance on forward-looking statements or information. Furthermore, Mineral Resources that are not Mineral Reserves do not have demonstrated economic viability.

Release – Eledon Presents Updated Long-Term Phase 2 BESTOW Extension Study Results at the International Congress of The Transplantation Society

Posted on September 22, 2026September 22, 2026 by [email protected]

Research News and Market Data on ELDN

September 22, 2026

PDF Version

Tegoprubart-treated patients maintained statistically significantly higher kidney function as measured by mean eGFR through 24 months, with an approximately 13 mL/min/1.73 m² advantage versus tacrolimus (71 vs. 58 mL/min/1.73 m²) at month 24

No rejections occurred in the tegoprubart arm beyond six months post-transplant, compared with seven in the tacrolimus arm

Tegoprubart granted U.S. FDA Fast Track designation for the prevention of rejection in kidney transplantation

Phase 3 LEGACY study expected to initiate in the fourth quarter of 2026

IRVINE, Calif., Sept. 22, 2026 (GLOBE NEWSWIRE) — Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced updated long-term data from its Phase 2 BESTOW clinical program evaluating tegoprubart in patients undergoing kidney transplantation, presented at the International Congress of The Transplantation Society, taking place September 20-23, 2026, in Sydney, Australia. The Company also announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to tegoprubart for the prevention of rejection in kidney transplantation.

“The BESTOW extension study data and continued improvements in kidney function and safety profile with tegoprubart versus standard of care tacrolimus further strengthen our belief in tegoprubart’s potential to become the new cornerstone immunosuppression therapy for kidney transplant recipients,” said David-Alexandre C. Gros, M.D., Chief Executive Officer of Eledon. “These long-term results, together with FDA Fast Track designation, support our plans to initiate the Phase 3 LEGACY study in kidney transplantation in the fourth quarter and advance tegoprubart as quickly as possible for transplant patients in need of better immunosuppressive options to improve long-term outcomes.”

The FDA’s Fast Track process is designed to facilitate the development and expedite the review of drugs that treat serious conditions and address significant unmet medical needs. Companies receiving Fast Track designation may be eligible for more frequent interactions with the FDA, rolling review of future marketing applications, and eligibility for Accelerated Approval and Priority Review.

Figure 1: Patients who completed treatment were those who completed 52 weeks of the study and received all planned doses of the randomized study drug. Data for M15 onward were collected from patients who completed treatment and enrolled in BESTOW EXTENSION. *p < 0.05 (treatment difference at M18, M21 and M24). Data extraction date: 31 Aug 2026. CI, confidence interval; eGFR, estimated glomerular filtration rate; M, Month; SEM, standard error of the mean; tac, tacrolimus; tego, tegoprubart.

Updated Phase 2 BESTOW Results

As of the data cutoff in the BESTOW long-term extension study, 90 patients had been followed through 18 months, and 81 patients had been followed through 24 months. Tegoprubart-treated patients maintained statistically significantly higher mean estimated glomerular filtration rate (eGFR), a measure of kidney graft function, at months 18, 21, and 24, with an approximately 13 mL/min/1.73 m² advantage over tacrolimus at month 24 (71 vs. 58 mL/min/1.73 m² [95% CI: 2.6, 23.3]). See Figure 1.
There were no reported cases of biopsy-proven acute rejection (BPAR) in the tegoprubart arm beyond six months post-transplant compared with seven in the tacrolimus arm. One new case of graft loss was observed in the tacrolimus arm.

Next Steps

Following its successful End-of-Phase 2 meeting with the FDA, Eledon remains on track to initiate its global Phase 3 trial of tegoprubart in kidney transplantation (LEGACY) in the fourth quarter of 2026. The LEGACY trial is expected to enroll approximately 600 patients, with a primary endpoint of non-inferiority of tegoprubart versus tacrolimus on a composite efficacy failure endpoint at 12 months, defined as a combination of biopsy-proven acute rejection (BPAR), graft loss, and death.

Details of the oral presentation at the International Congress of The Transplantation Society are below:

Title: Phase 2 BESTOW trial and the BESTOW EXTENSION: Evaluating the long-term safety and efficacy of tegoprubart in preventing kidney transplant rejection
Presenter: Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief, Division of Transplantation, John S. Najarian Surgical Chair in Clinical Transplantation, Department of Surgery, University of Minnesota; Executive Medical Director, Solid Organ Transplant Service Line, M Health Fairview
Session Title: Novel immunosuppression
Session Date and Time: Tuesday, September 22, 2026, from 8:00 a.m. to 9:00 a.m. AEST
Session Room: Room C4.9
Presentation Time: 8:00 a.m. AEST

About Eledon Pharmaceuticals and tegoprubart

Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40L biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, liver transplantation and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California. For more information, please visit the Company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; X

Forward-Looking Statements

This press release contains forward-looking statements that involve substantial risks and uncertainties. Any statements about the company’s future expectations, plans and prospects, including statements about planned clinical trials, the development of product candidates, expected timing for initiation of future clinical trials, expected timing for receipt of data from clinical trials, as well as other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “estimates,” “intends,” “predicts,” “projects,” “targets,” “looks forward,” “could,” “may,” and similar expressions, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Specifically, our ability to achieve our anticipated future development and corporate milestones depends on our ability to obtain additional financing on acceptable terms. Forward-looking statements are inherently uncertain and are subject to numerous risks and uncertainties, including: our short operating history and shifts in our business strategy; our operating losses since inception; our need for additional funding to develop our lead drug candidate and our ability to secure additional funding on acceptable terms or at all; the impact of issuances of our common stock, including in the possibility of dilution or a decline in our stock price; our ability to successfully develop our product candidates; unfavorable global economic and financial market conditions; the regulatory environment of our business and our ability to obtain required regulatory approvals; results of non-clinical studies and clinical trials, and risks that non-clinical studies or early clinical trials may not be predictive of results of later-stage clinical trials; delays or difficulties in enrollment of patients in clinical trials; our ability to attract and retain our executives and key employees; legislation of the pharmaceutical and healthcare industries; cybersecurity and data privacy risks; the ability of our products to achieve marketing approval; competition in our industry; our ability to obtain insurance coverage; our dependence on contract research organizations; our ability to protect our intellectual property; public health crises; our ability to maintain proper and effective internal control over financial reporting and other risks disclosed in our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission on March 19, 2026. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors. These risks and uncertainties, as well as other risks and uncertainties that could cause the company’s actual results to differ materially from the forward-looking statements contained herein, are discussed in our Annual 10-K, and other filings with the U.S. Securities and Exchange Commission, which can be found at www.sec.gov. Any forward-looking statements contained in this press release speak only as of the date hereof and not of any future date, and the company expressly disclaims any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
[email protected]

Media Contact:

Jenna Urban
CG Life
(212) 253 8881
[email protected]

Source: Eledon Pharmaceuticals, Inc

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/48a2ff2b-c346-426c-a886-6377e5c48d1a